EX-99.B 4 y64598exv99wb.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99(b) MERCK & CO., INC. GROSS PRODUCT SALES DETAIL
3Q `02 vs. 3Q `01 -------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------- ----- ----- ---- ---- ------- ------- VIOXX 2% $ 810 -4% $ 600 24% $210 ARCOXIA N/M 10 N/M -- N/M 10 VASOTEC / VASERETIC -24% 185 N/M (10) -9% 195 PRINIVIL / PRINZIDE -38% 165 -43% 140 25% 25 COZAAR / HYZAAR 8% 585 -5% 260 23% 325 MEVACOR -50% 55 -56% 40 -25% 15 ZOCOR 11% 1,925 6% 1,340 24% 585 AGGRASTAT 0% 25 0% 15 N/M 10 SINGULAIR 9% 380 0% 270 38% 110 MAXALT 36% 95 25% 75 100% 20 PROPECIA 0% 55 20% 30 -17% 25 PROSCAR 18% 165 36% 95 0% 70 PRIMAXIN 11% 155 38% 55 0% 100 INVANZ N/M 5 N/M -- N/M 5 CANCIDAS N/M 30 N/M 20 N/M 10 PEPCID -57% 15 -75% 5 -33% 10 FOSAMAX 11% 500 -2% 315 42% 185 CRIXIVAN/STOCRIN -39% 70 -69% 20 0% 50 TIMOPTIC/TIMOPTIC XE -20% 40 -67% 5 0% 35 TRUSOPT/COSOPT 15% 115 22% 55 9% 60 HEPATITIS VACCINES -15% 85 -22% 70 50% 15 VIRAL VACCINES -9% 145 -7% 140 -50% 5 OTHER VACCINES N/M 55 N/M 45 N/M 10
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. GROSS PRODUCT SALES DETAIL
9 MONTHS 2002 OVER 2001 ------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ---------------------- ----- ----- ---- ---- ------- ------- VIOXX 15% $2,305 12% $1,715 24% $ 590 ARCOXIA N/M 20 N/M -- N/M 20 VASOTEC / VASERETIC -28% 580 N/M -- -16% 580 PRINIVIL / PRINZIDE -12% 830 -12% 765 -7% 65 COZAAR / HYZAAR 12% 1,610 16% 740 9% 870 MEVACOR -51% 190 -56% 145 -25% 45 ZOCOR 12% 5,155 11% 3,555 12% 1,600 AGGRASTAT -6% 80 -27% 40 33% 40 SINGULAIR 7% 1,100 1% 805 31% 295 MAXALT 15% 235 9% 180 38% 55 PROPECIA -3% 155 -12% 75 7% 80 PROSCAR 0% 410 0% 210 0% 200 PRIMAXIN -2% 430 4% 135 -5% 295 INVANZ N/M 10 N/M 5 N/M 5 CANCIDAS N/M 70 N/M 45 N/M 25 PEPCID -86% 45 -93% 20 -50% 25 FOSAMAX 32% 1,700 30% 1,220 37% 480 CRIXIVAN/STOCRIN -33% 225 -43% 85 -24% 140 TIMOPTIC/TIMOPTIC XE -24% 125 -56% 20 -13% 105 TRUSOPT/COSOPT 8% 325 7% 155 10% 170 HEPATITIS VACCINES -17% 225 -18% 200 0% 25 VIRAL VACCINES 4% 440 8% 425 -50% 15 OTHER VACCINES N/M 95 N/M 65 N/M 30
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. NET PRODUCT SALES DETAIL
3Q `02 vs. 3Q `01 ----------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------- ----- ----- ---- ---- ------- ------- VIOXX 3% $ 755 -3% $ 545 24% $ 210 ARCOXIA N/M 10 N/M -- N/M 10 VASOTEC / VASERETIC -24% 185 N/M (10) -9% 195 PRINIVIL / PRINZIDE -24% 80 -35% 55 25% 25 COZAAR / HYZAAR 8% 550 -8% 225 23% 325 MEVACOR -33% 30 -40% 15 -25% 15 ZOCOR 9% 1,470 1% 885 24% 585 AGGRASTAT -20% 20 -33% 10 N/M 10 SINGULAIR 11% 350 2% 240 38% 110 MAXALT 23% 80 9% 60 N/M 20 PROPECIA 0% 55 20% 30 -17% 25 PROSCAR 19% 155 42% 85 0% 70 PRIMAXIN 11% 150 43% 50 0% 100 INVANZ N/M 5 N/M -- N/M 5 CANCIDAS N/M 30 N/M 20 N/M 10 PEPCID -50% 10 -100% -- -33% 10 FOSAMAX 9% 455 -5% 270 37% 185 CRIXIVAN/STOCRIN -41% 65 -75% 15 0% 50 TIMOPTIC/TIMOPTIC XE -20% 40 -67% 5 0% 35 TRUSOPT/COSOPT 11% 105 13% 45 9% 60 HEPATITIS VACCINES -7% 65 -17% 50 N/M 15 VIRAL VACCINES -6% 145 -3% 140 N/M 5 OTHER VACCINES N/M 80 N/M 70 N/M 10
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. NET PRODUCT SALES DETAIL
9 MONTHS 2002 OVER 2001 ----------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------------------- ----- ----- ---- ---- ------- ------- VIOXX 17% $2,145 14% $1,555 24% $ 590 ARCOXIA N/M 20 N/M -- N/M 20 VASOTEC / VASERETIC -27% 580 -100% -- -16% 580 PRINIVIL / PRINZIDE -12% 470 -13% 405 -7% 65 COZAAR / HYZAAR 10% 1,505 11% 635 9% 870 MEVACOR -58% 90 -71% 45 -25% 45 ZOCOR 8% 3,840 5% 2,240 12% 1,600 AGGRASTAT -6% 75 -30% 35 33% 40 SINGULAIR 5% 995 -3% 700 31% 295 MAXALT 14% 205 7% 150 38% 55 PROPECIA -3% 155 -12% 75 7% 80 PROSCAR -3% 385 -5% 185 0% 200 PRIMAXIN -5% 410 -4% 115 -5% 295 INVANZ N/M 10 N/M 5 N/M 5 CANCIDAS N/M 65 N/M 40 N/M 25 PEPCID -85% 40 -93% 15 -50% 25 FOSAMAX 29% 1,555 26% 1,075 35% 480 CRIXIVAN/STOCRIN -33% 215 -44% 75 -24% 140 TIMOPTIC/TIMOPTIC XE -22% 125 -50% 20 -13% 105 TRUSOPT/COSOPT 5% 305 0% 135 10% 170 HEPATITIS VACCINES -19% 170 -22% 145 0% 25 VIRAL VACCINES 4% 430 8% 415 N/M 15 OTHER VACCINES N/M 165 N/M 135 N/M 30
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. CONSOLIDATED THIRD QUARTER
3Q `02 3Q `01 % CHG. ------ ------ ------ TOTAL SALES $ 12,892.9 $ 11,919.6 8% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 10,201.6 $ 9,136.5 ---------- ---------- Materials & Production 8,080.1 7,082.8 Marketing & Administrative 1,562.7 1,525.3 Research & Development 676.9 590.3 Equity Income From Affiliates (188.7) (164.1) Other (Income)/Expense, Net 70.6 102.2 PRE-TAX INCOME $ 2,691.3 $ 2,783.1 TAXES $ 807.3 $ 834.9 TAX RATE 30.0% 30.0% NET INCOME $ 1,884.0 $ 1,948.2 -3% EPS - ASSUMING DILUTION $ 0.83 $ 0.84 -1% AVG. # SHARES - ASSUMING DILUTION 2,265.9 2,312.4
3Q `02 % CHG. VOL PX FX ------- ------- ---- ---- ---- TOTAL SALES $12,890 8% 0 7 1 ------- ---- ---- ---- ---- Total Pharmaceutical Sales 5,515 1% -2 2 1 ------- ---- ---- ---- ---- U.S. 3,390 -6% -12 6 0 Foreign 2,125 14% 14 -3 3 Other Medco Sales 7,375 14%
Exhibit 99(b) MERCK & CO., INC. CONSOLIDATED NINE MONTHS YEAR TO DATE
2002 2001 % CHG. ---------- ---------- ---------- TOTAL SALES $ 37,871.9 $ 35,157.8 8% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 30,358.1 $ 27,413.7 ---------- ---------- Materials & Production 24,353.5 21,334.1 Marketing & Administrative 4,505.3 4,669.0 Research & Development 1,838.4 1,740.0 Equity Income From Affiliates (550.7) (557.8) Other (Income)/Expense, Net 211.6 228.4 PRE-TAX INCOME $ 7,513.8 $ 7,744.1 TAXES $ 2,254.1 $ 2,323.2 TAX RATE 30.0% 30.0% NET INCOME $ 5,259.7 $ 5,420.9 -3% EPS - ASSUMING DILUTION $ 2.31 $ 2.33 -1% AVG. # SHARES - ASSUMING DILUTION 2,281.0 2,329.1
2002 % CHG. VOL PX FX ------- ----- ---- ---- ---- TOTAL SALES $37,870 8% 2 6 0 ------- ---- ---- ---- ---- Total Pharmaceutical Sales 15,570 -1% 0 0 -1 ------- ---- ---- ---- ---- U.S. 9,690 -4% -6 2 0 Foreign 5,880 4% 9 -2 -3 Other Medco Sales 22,300 15%
Exhibit 99(b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2002 ================================================================================ OTHER (INCOME)/EXPENSE, NET
3Q `02 3Q `01 YTD 2002 YTD 2001 ------ ------ -------- -------- INTEREST INCOME $(107.3) $(114.6) $(311.2) $(380.3) INTEREST EXPENSE 99.9 121.8 292.7 355.2 EXCHANGE (GAINS)/LOSSES 8.3 1.5 10.9 (18.6) MINORITY INTERESTS 59.1 72.3 169.7 218.3 AMORTIZATION OF GOODWILL AND INTANGIBLES 51.1 83.7 153.5 244.8 Other, net (40.5) (62.5) (104.0) (191.0) ------- ------- ------- ------- TOTAL $ 70.6 $ 102.2 $ 211.6 $ 228.4 ------- ------- ------- -------
================================================================================ JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 3Q `02 3Q `01 YTD 2002 YTD 2001 ------ ------ ------ -------- -------- IVOMEC, HEARTGARD, other avermectins $130 $130 $ 350 $ 365 FRONTLINE 150 100 410 340 Biologicals 90 85 275 255 Other Animal Health 40 45 130 145 Poultry Genetics 55 50 165 155 ---- ---- ------ ------ TOTAL MERIAL SALES $465 $410 $1,330 $1,260 ---- ---- ------ ------
AVENTIS PASTEUR-MSD 3Q `02 3Q `01 YTD 2002 YTD 2001 ------ ------ ------ -------- -------- HEPATITIS VACCINES $ 20 $ 20 $ 50 $ 70 VIRAL VACCINES 10 10 25 35 Other Vaccines 175 125 325 265 ---- ---- ------ ------ TOTAL AP-MSD SALES $205 $155 $ 400 $ 370 ---- ---- ------ ------
================================================================================ TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
2002 MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 20 121 141 SECOND QUARTER 21 119 140 THIRD QUARTER 20 110 130 ---- ---- ---- YEAR TO DATE 61 350 411 ---- ---- ----
2001 MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 18 120 138 SECOND QUARTER 18 115 133 THIRD QUARTER 19 110 129 ---- ---- ---- YEAR TO DATE 55 345 400 ---- ---- ----